FY20 Investor Presentation

February 2021

Disclaimer

The material contained in this presentation is intended to be general background information on Imricor Medical Systems Inc ("Imricor") and its activities.

The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (US GAAP) and are denominated in US dollars.

This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 21E of the US Securities Exchange Act of 1934. Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding our intent, belief or current expectations with respect to our business and operations, market conditions, results of operations and financial condition.

We use words such as 'will', 'may', 'expect', 'intend', 'seek', 'would', 'should', 'could', 'continue', 'plan', 'estimate', 'anticipate', 'believe', 'probability', 'risk', 'aim', or other similar words to identify forward-looking statements. These forward-looking statements reflect our current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond our control, and have been made based upon management's expectations and beliefs concerning future developments and their potential effect upon us. There can be no assurance that future developments will be in accordance with our expectations or that the effect of future developments on us will be those anticipated. Actual results could differ materially from those which we expect, depending on the outcome of various factors. Factors that may impact on the forward-looking statements made include, but are not limited to, those described in the section titled 'Risk factors' in Imricor's prospectus dated 7 August 2019. When relying on forward-looking statements to make decisions with respect to us, investors and others should carefully consider such factors and other uncertainties and events. We are under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction.

Presenters

Steve Wedan

Chair & CEO

- Mr Wedan is the Chief Executive Officer and Co-Founder of Imricor
- Mr Wedan has over 30 years of medical devices experience particularly in the field of design engineering of MRI and ultrasound systems
- Prior to Imricor, Mr Wedan was a Chief Technology Officer at Applied Biometrics and Development Engineer at GE Healthcare
- Mr Wedan holds a Bachelor of Science in Electrical Engineering from Michigan Technology University (summa cum laude), and a Master of Science in Electrical Engineering from Marquette University

Lori Milbrandt

Chief Financial Officer

- Ms Milbrandt has served as the Company's Chief Financial Officer since 2007, initially on a contract basis and since May 2018, as a full-time employee of Imricor.
- Ms Milbrandt has over 30 years of accounting, finance, and HR experience. Prior to transitioning to the role of CFO on a full-time basis, Ms Milbrandt was a contract CFO for several medical device companies. Ms Milbrandt has previously held management positions with companies including Microvena, ev3, and DiaSorin (FKA Incster) and spent the first seven years of her career with KPMG.
- Ms Milbrandt holds a Bachelor of Business Administration from the University of Wisconsin-Eau Claire and a Master of Business Administration (Finance) from the University of St. Thomas.

Agenda



Key achievements in 2020

CE mark approval received

enabling the sale of Imricor's products in the European Union

Successful commercial launch

at Heart Centre Dresden also providing training to future sites

9 sites contracted[1]

with a growing pipeline of new sites

Sales agreement with Philips

enabling Philips to sell Imricor's capital equipment as part of iCMR lab installation package

Strategic agreements signed

that further promote future iCMR lab adoption

Solid progress on growth strategies

remaining on track with initiatives to expand indications and geographies

1. As at 30 December 2020

Lab roll out update



COVID situation in key target geographies



- Second COVID-19 wave in Europe was worse than expected followed by an unanticipated third wave across The Netherlands & Switzerland in November and December
- Across Germany the initial stabilisation in daily cases was unable to be sustained
- Additional containment measures were put in place across key target geographies of the Netherlands & Germany, resulting in hard lock downs from 15 December
- Containment measures in Germany have been extended to 7 March 2021 & The Netherlands until 2 March
- COVID-19 vaccinations now underway across both countries with approximately 5-6% of the population having received a vaccination dose
- Vaccinations combined with falling daily case rates are expected to result in easing of restrictions in the coming weeks

Chart Source: European Centre for Disease Prevention and Control

COVID impacts in the second half of 2020

- Due to hospital closures associated with strict COVID-19 containment measures implemented across key target geographies of Germany and The Netherlands, Imricor experienced delays in signing agreements with new clinical sites in the last quarter of 2020
- Imricor is working closely with contracted sites to schedule installation, training and the commencement of cases as soon as restrictions allow, as evidenced by the recent commencement of cases at Maastricht University Medical Centre
- Training and installation teams in Europe supported by US based teams are ready to proceed quickly as COVID-19 restrictions ease
- Limited procedure volumes and therefore low consumable sales during the period due to hospital closures and restrictions on elective surgery
- Redeployed some manufacturing workforce to product development, with a focus on building products for future clinical trials to support expanded indications
- Continued delivery of online events and education seminars in lieu of industry trade events

Future acceleration in lab rollout plans underpinned by strong pipeline

9 sites with agreements to purchase Imricor's products

Nine clinical sites now contracted across Germany, The Netherlands & France

- Dresden Heart Centre, Germany, a training Centre of Excellence;
- Haga Hospital, The Netherlands;
- Amsterdam University Medical Centre, The Netherlands;
- Leipzig Heart Centre, Germany, a training Centre of Excellence;
- Rhön Clinic Bad Neustadt Campus, Germany;
- Maastricht University Medical Centre, The Netherlands;
- South Paris Cardiovascular Institute, France; and
- Lübeck University Heart Centre, UKSH, Germany.
- Münster University Hospital, Germany

Initial sites (e.g. Dresden, Leipzig) are set up as training Centres of Excellence for sites that follow

Strong pipeline

- Discussions well advanced across a number of sites, many at final stage of review and execution
- Strong and growing pipeline of potential sites supported by increasing awareness and education of Imricor's product
- Agreement with Sana GPO provides access to ~80 sites for sales & marketing
- Further enhanced by Philips sales distribution agreement and collaborative relationship with Siemens to drive lab adoption
- A well-developed longer-term pipeline aligned with capital cycles of clinical sites
- Expecting to recommence signing new agreements during the second quarter, accelerating in the second half of 2021

Business Update



Maintaining a strong focus on growth drivers through COVID

Despite the COVID-19 pandemic stalling lab roll out plans during 2020, Imricor maintained clear focus on progressing initiatives across the business to support future growth

- ✓ Launched online training and education seminars
- ✓ Contracted nine sites and significantly grew the pipeline of potential new sites
- ✓ Signed a sales agreement with Philips to sell Imricor's capital equipment as part of Phillips iCMR implementation package & working towards a similar agreement with Siemens
- ✓ Signed a master purchasing agreement with Sana GPO, streamlining access to ∽80 sites performing cardiac ablations
- ✓ Awarded a contract from the US National Institutes of Health (NIH) to develop an MRI compatible myocardial biopsy system
- ✓ Entered into agreements with Optoacoustics & Osypka to provide a sales channel for the supply of products to Imricor's customers for iCMR ablation procedures
- ✓ Progressed strategy around regulatory approvals to expand indications and geographic reach
- ✓ Continued to expand the workforce to ensure capacity and capability to deliver Imricor's growth strategy

Partnering to drive growth in clinical sites

Imricor entered into a number of agreements in 2020 that promote future iCMR lab adoption

PHILIPS

- A worldwide leading manufacturer of MRI equipment
- Non-exclusive collaborative sales distribution agreement
- Enables the sale of Imricor's capital product, Advantage-MR EP Recorder/Stimulator System as part of Philips comprehensive iCMR lab installation package[1]
- Enables the extensive Philips sales force to drive iCMR lab adoption
- Imricor continues to be the exclusive provider of its consumable devices

Sana Einkauf & Logistik

- Largest Group Purchasing Organisation in Germany, with 600 cooperating hospitals and medical institutions across Germany & Switzerland
- Imricor products included in approved catalogue, establishing pricing and eliminating time consuming contract negotiations
- Streamlines access to ~80 sites that perform cardiac ablations for sales and marketing activities

Opto acoustics

- Leading provider of innovative optical communication solutions for MRI applications
- Facilitates the introduction of the IMROC™ Wireless Multichannel Communication System to Imricor customers
- Innovative noise cancelling communication technology supporting iCMR adoption
- Establishes an important sales channel ensuring availability as new sites are launched
- Referral fee-based agreement

OSYPKA
Technology for an active life

- Leading German producer of radiofrequency ablation generators
- Under the agreement Imricor will sell Osypka's HAT 500 radiofrequency ablation generator system to customers for use in iCMR ablation procedures
- The HAT 500 is compatible with Imricor's Advantage-MR EP Recorder/Stimulator, replacing the discontinued Abbott IBI T11 ablation generator.

1. In European countries that recognise the CE mark

Pipeline growth supported by early clinical success

Early clinical success and excellent physician feedback is driving growing interest in Imricor's products and the opportunity to establish a new standard of care in the treatment of heart arrythmias, with particular focus on expanded indications

"This is beautiful. It is better than fluoroscopy. In fluoroscopy you can only imagine the anatomy. Here you see it" – Dr Christopher Piorkowski, Dresden Heart Centre

"Today in our ablation we realised that we were limited in the past, and now we can see what we are doing. While we have just started in iCMR, it is obvious to see the future of this technology and where it will take us and patient treatment."" – Dr. Marisevi Chaldoupi, Maastricht University Medical Centre

"Performing this procedure under MRI allows for direct peri-procedure visualization of ablation lesions. This has the potential to improve clinical results substantially" – Dr. Marco Gotte, Amsterdam University Medical Centre

"In all respect, this is a major step forward for patients with cardiac arrhythmias and also for hospitals" – Dr. Ivo van der Bilt, Haga Hospital

Status of 3rd party active tracking and mapping systems

While yet to achieve CE mark approval, the availability of the Philips and Siemens active tracking and mapping systems is not a constraining factor on lab growth or the commencement of new clinical trials with Active Catheter Imaging now available across both platforms

PHILIPS Healthcare

iSuite

- Research version released for hospitals to purchase
- Local Ethics Committee (or IRB) approval required to use during clinical cases (our previously described plan)
- Full commercial release timing not disclosed
- Active Catheter Imaging now also developed on Philips's platform, allowing sites to commence AFL procedures without installing iSuite system

SIEMENS Healthineers

"Monte Carlo"[1]

- Research version placed at some key sites
- Local Ethics Committee (or IRB) approval required to use during clinical cases
- Full commercial release timing not disclosed
- Active Catheter Imaging on Siemens platform allows site to start AFL ablations without Ethics Committee approval and without installing the research version

1. Not the final product name

Continued investment in business capability and capacity to deliver growth

Workforce growth continues to expand capability across the company with 27 new hires in 2020 to support commercialisation and growth strategies, including hires from high calibre organisations within the med-tech sector



Market opportunity

A strong and growing market in cardiac ablation

A large global addressable market with high growth potential supported by favourable growth drivers

Drivers of Global Catheter Ablation Market

- Increased incidence of cardiac disease
- Shift towards minimally invasive procedures
- Cost effectiveness of catheter ablation as treatment option

EU and US Cardiac Ablation Market



Sources:
Millennium Research Group *Electrophysiology Mapping and Ablation Devices Europe 2021* July 2020
Millennium Research Group *Electrophysiology Mapping and Ablation Devices US 2021* June 2020

Catheter Volume and Ablation Procedures Types

Catheter Volume



Breakdown of Ablation Procedures



Sources:
Millennium Research Group *Electrophysiology Mapping and Ablation Devices Europe 2021* July 2020
Millennium Research Group *Electrophysiology Mapping and Ablation Devices US 2021* June 2020

Core strategies to drive future growth

Imricor's strategy is focused on the two drivers that are key to revenue growth – the number of iCMR labs and the number of procedures performed using Imricor's consumables in each lab

Go to market strategies

- Collaborative sales distribution agreement with Philips
- Strategic relationship with Siemens
- Growing awareness through sales and marketing activities
- Engagement with Key Opinion Leaders
- Comprehensive training and support at clinical sites

Geographic expansion

- CE mark approval enables the sale of products in the EU
- Strategy to obtain FDA approval in the US well advanced and targeting clinical trials in 2021-2022
- Local agent to be selected to support TGA approval in Australia

Expanded indications

- Ablation catheter has CE mark approval for the treatment of atrial flutter
- Atrial flutter comprises only 23% of ablation procedures in the EU
- Planning to commence clinical trials to expand CE mark approval to other indications in 2021

Expanded Product Range

- Diagnostic catheter under development to support margin improvement
- Steerable sheath and transseptal needle supporting expanded indications
- NIH contract to develop a device to biopsy the inner walls of the heart guided by MRI
- Other opportunities beyond cardiac ablation

Sales and marketing strategy

Imricor's sales and marketing strategy is designed to specifically address the two key drivers of revenue growth: the number of iCMR labs and the number of procedures performed with Imricor's consumables in each lab

Driving lab adoption in collaboration with Siemens and Philips

- Collaborative sales agreement with Philips leveraging sales force across the EU
- Joint Development Agreement and close collaboration regarding sales and marketing with Siemens
- Procedures in some sites commencing in diagnostic MRI suites while iCMR labs are being built
- Early support and cross-site training to ensure early success and ease of use

Comprehensive training and support at clinical sites

- Site-specific support plans in place to drive increased utilisation at each site as COVID restrictions are lifted
- Growing European clinical support team for increased coverage

Marketing focus on product awareness and educational programs

- Launch of corporate procedural workflow video in 2020
- Comprehensive pre-recorded and live-broadcast procedure plan for education and use in congresses in 2021
- Planning more virtual and live educational activities in 2021

A phased approach to geographic expansion

Netherlands
Clinical sites established at Haga Hospital, Amsterdam UMC and Maastricht University Medical Centre

Germany
Five clinical sites with signed purchase agreements across Germany
Imricor products included in Sana GPO approved catalogue of materials

France
Clinical site with signed purchase agreement at South Paris Cardiovascular Institute

Switzerland
Imricor products included in Sana GPO approved catalogue of materials



Europe
CE mark achieved

PHASE 1
The Netherlands, Austria, Germany and Switzerland.

PHASE 2
France, Hungary, Nordics.

PHASE 3
The rest of Europe.

Australia

Local agent to be selected in March 2021.

Detailed approval strategy in planning phase.

United States

FDA strategy well advanced.

Discussions with FDA underway.

Remain on track, targeting a clinical trial in 2021-2022.

Driving growth through expanding indications

Priority target is Ventricular Tachycardia (VT) driven by growing procedure rates and high value of iCMR for VT

1 Ventricular Tachycardia

- Ablation in the left and right ventricles
- Often uses transseptal puncture kit (in Imricor product pipeline)
- Requires tracking and mapping system (from MRI manufacturer)
- Requires defibrillation in MRI (3rd party device in development)
- Requires 12-lead ECG in MRI (3rd party device in development)
- All required devices on track for use in VT clinical trial



2 Atrial Fibrillation

- Ablation in the left atrium
- Requires transseptal puncture kit (in Imricor product pipeline)
- Requires tracking and mapping system (from MRI manufacturer)
- Benefits from defibrillation and 12-lead ECG in MRI

Developing product lines to support expanded indications & margin improvement

Diagnostic Catheter

A diagnostic catheter can sense electrical signals flowing through the heart and provide cardiac stimulation but is not used for ablation. A diagnostic and ablation catheter is required to perform atrial flutter procedures - currently sold by Imricor in a two-catheter set comprising two ablation catheters.

- Development and regulatory strategy well advanced
- Scaled down second-generation Vision-MR ablation catheter
- Utilising advancements from the next generation ablation catheter to create a more consistent product line for physicians and reduce production costs to drive a higher gross margin
- Aiming for late 2021 or early 2022 commercial release, pending CE mark approval

Steerable Sheath and Transseptal Needle



The steerable sheath and transseptal needle are intended to be used together in procedures where access to the left side of the heart is required and the physician opts to access the left side by crossing the intra-atrial septum

- Prototype phase
- Regulatory strategy being developed
- Fully staffed execution
- Aiming to be ready for clinical trials in 2021

First potential product line expansion beyond cardiac ablation

Myocardial Biopsy System

- In September 2020, the US National Institutes of Health (NIH) awarded Imricor with a contract to develop an MRI compatible myocardial biopsy system
- Under the agreement Imricor will receive US$399,539 over the period of 12 months to develop a prototype system of devices that can biopsy the inner walls of the heart, while using MR imaging to guide the procedure
- Imricor's potential first product line expansion beyond cardiac ablation
- Addressable market for an MRI compatible biopsy system is believed to be significant and likely similar to that for Imricor's cardiac ablation catheter
- Market research to determine market opportunity is underway & expected to be complete in Q2 2021

Financial Performance



Profit and loss

US$'000	FY19	FY20
Revenue	640	702
Operational expenses	(3,496)	(6,833)
R&D expenses	(3,434)	(5,297)
Other expenses	(14)	(20)
EBITDA	**(6,304)**	**(11,448)**
Depreciation & Amortization	(257)	(528)
EBIT	**(6,561)**	**(11,976)**
Finance costs	(1,017)	(272)
Foreign exchange loss	216	(198)
Convertible note expense[1]	(5,932)	-
Net loss after finance costs and before tax	**(13,294)**	**(12,446)**
Income tax benefit	-	-
Net loss after tax	**(13,294)**	**(12,446)**

Commentary

- Operational expenses increased in 2020 due primarily to additional staffing ($1,950k), D&O insurance ($538k) and public company costs ($465k)
- R&D expenses increased in 2020 due primarily to additional staffing ($1,457k)



1. Comprising non-recurring interest expense, down round expense and beneficial conversion feature associated with convertible notes converted to equity on completion of IPO

Cashflow

US$'000	FY19	FY20
Net loss	**(13,294)**	**(12,446)**
Convertible note related expenses	6,684	-
Other non-cash adjustments	548	1,548
Change in other assets and liabilities	(566)	(1,333)
Operating cash flows	**(6,628)**	**(12,231)**
Investing cash flows	**(529)**	**(774)**
Proceeds from issuance of common stock (net)	7,222	33,407
Proceeds from convertible notes	1,746	-
Proceeds from financing obligation	1,700	-
Other financing activities	(217)	(382)
Financing cash flows	**10,451**	**33,025**
Net change in cash	3,294	20,020
Effect of foreign currency changes on cash	166	71
Cash at 31 December	**5,049**	**25,140**

Commentary

- Other non-cash adjustments are primarily related to deprecation and stock-related compensation expense
- Net operating cash outflows increased $5.6 million on the prior comparative period due primarily to additional staffing, D&O insurance, public company costs and building inventory
- Investing cash outflows consisted of purchases of manufacturing and R&D equipment and payments for security deposits. During 2020, investing cash outflows also includes leasehold improvements and furniture related to the build out of additional R&D space
- 2019 Proceeds from issuance of common stock includes $7.0 million related to the Company's IPO and $0.2 related to the exercise of options and warrants
- 2019 Proceeds from financing obligation relates to the sale-leaseback of the Company's MRI scanner
- 2020 Proceeds from issuance of common stock includes $12.6 million related to the Company's February placement, $19.2 million related to the Company's November placement, $1.1 million related to the Company's December Security Purchase Plan and $0.5 related to the exercise of options and warrants

Balance sheet

US$'000 (31 December)	Dec-19	Dec-20
Cash and cash equivalents	5,049	25,140
Accounts receivable	256	223
Inventory	1,221	3,070
Other current assets	288	492
Total current assets	**6,814**	**28,925**
PP&E, net	2,285	3,095
Accounts receivable-long term	277	239
Other non-current assets	193	224
Operating lease right of use assets	453	795
Prepaid service agreement	500	291
Total non-current assets	**3,708**	**4,644**
Total assets	**10,522**	**33,569**
Accounts payable	541	529
Accrued expenses	368	1,069
Current portion of contract liabilities	15	40
Current lease liabilities	501	661
Total current liabilities	**1,425**	**2,299**
Other long-term liabilities	-	67
Non-current lease liabilities	1,471	1,837
Deferred revenue (non-current)	593	550
Total non-current liabilities	**2,064**	**2,454**
Total liabilities	**3,489**	**4,753**
Share capital	47,459	81,688
Accumulated losses	(40,426)	(52,872)
Total equity	**7,033**	**28,816**

Commentary

- Current assets: Year over year increase due to proceeds from its February and November placement and December Security Purchase Plan and inventory build in preparation of European commercialisation, which was impacted by COVID
- Non-current assets: Year over year increase due primarily to purchases of manufacturing and R&D equipment as well as leasehold improvements and furniture related to the build out of additional R&D space
- Accrued expenses: Increases due primarily to increased bonus accrual (related to significant increase in headcount), accruals for professional services and inventory purchases where invoices had not yet been received
- Convertible notes: The notes and accrued interest converted to conversion shares as a result of the Company's IPO
- Equity: Increase due to 2020 placements and Security Purchase Plan

Initiatives to support future growth and drive financial performance

Support margin improvements

- Support the continued increase in manufacturing yields and reduced cycle times
- Support development and process improvements for ablation catheter, new diagnostic catheter and cables
- Reduce sterilisation cycle costs by 75%

Implement processes for volume growth

- Implemented robust inventory management system

Human resources

- Support recruiting efforts across all departments
- Manage onboarding of new employees, ensuring compliance with legal requirements across several countries
- Automation of employee benefit platforms to reduce internal resource need

Outlook



Our focus for the year ahead

Imricor's focus for 2021 is on accelerating its product launch throughout the EU while pursuing growth opportunities that position the company strongly in the coming years

Commercialisation

- Continued lab roll out with focus on acceleration in the last half of 2021
- Increased utilisation of the Philips sales force to drive the pipeline of iCMR labs
- Ongoing development of lab pipeline through Imricor's marketing activities and collaboration with Siemens

Products

- Launch of second-generation ablation catheter
- Submit diagnostic catheter for CE mark approval
- Steerable sheath and transseptal needle ready for clinical trials that support expanded indications

Growth Initiatives

- Progress regulatory approvals to expand into Australia and the US
- Advance strategy around clinical trials expanding indications in Europe
- Progress development of MRI compatible biopsy system
- GM improvement initiatives to deliver benefits in future years

Q&A

Appendices

An overview of Imricor

- Founder-led business with deep med-tech experience management team
- The world's first commercially available MRI compatible catheter ablation devices
- Strong IP portfolio and patent protection
- Large addressable market, growing to over $4bn[1] by 2022, with favourable market drivers
- Compelling value propositions for all stakeholders
- Leveraging strategic relationships with Philips Healthcare and Siemens Healthineers

1. United States and Europe (comprises the UK, Germany, France, Spain and Italy)

Heart arrythmias and conventional treatment options

In the absence of MRI-compatible catheter ablation devices, physicians have been unable to take advantage of the potential benefits related to MRI guided ablation procedures for treating arrhythmias

Arrhythmias

- An arrhythmia is an abnormal heart rhythm
- Certain untreated arrhythmias can lead to serious cardiac conditions, such as blood clotting, stroke and/or death
- Rising global incidence of arrhythmias driven by secular demographic trends, such as aging population and increased occurrence of hypertension, obesity and diabetes

Conventional Treatment Options

- Conventional catheter ablation procedures performed guided by x-ray and aided by 3D mapping and tracking tools
- Antiarrhythmic drugs which focus on changing the electrical properties of cardiac tissue
- Implantable devices such as a pacemaker or defibrillator

The problems we are trying to solve through MRI guided ablation procedures

	Visualisation	Procedure effectiveness	Cost	Procedure time	Safety
Existing Challenges	• X-ray imaging provides poor heart visualisation • 3D mapping and tracking tools assist but have limitations • Inability to determine creation of permanent lesions	• Inability to determine permanency of lesions can negatively impact single procedures success rates which vary from 38% to over 95% depending on the type of arrythmia	• Repeat procedures can result in higher overall medical costs • A US study over a 5-year period showed medical costs for patients who require repeat AF ablations is 294% higher	• Conventional 3D mapping systems require additional time associated with image creation and calibration • Average procedure time for a conventional AFL ablation reported at 88 minutes	• Patient and doctor exposed to radiation during x-ray guided ablations • Occupational injuries can arise from heavy lead protective garments worn by medical professionals
Imricor's Solution	• Soft tissue of the heart is clearly visible in real-time • Both 2D and 3D imaging available • Non-permanent lesions can be identified during the procedures and filled	• Reduced likelihood of a repeat procedure due to ability to determine permanency of lesions • Imricor's clinical trial delivered a 100% chronic success rate for AFL procedures	• Per-procedure cost comparable to the cost of a conventional x-ray guided procedure • Increased effectiveness, fewer procedures and lower overall treatment cost	• Physician inserts catheter and commences procedure immediately • Average procedure time for MRI-guided AFL ablations is 48 minutes • Faster procedure times could enable more procedures	• MRI generates no radiation and eliminates risk of radiation injury • Physicians do not need to wear heavy protective garments

Key drivers of Imricor's growth

Imricor's strategy is focused on the two drivers that are key to revenue growth – the number of iCMR labs and the number of procedures performed using Imricor's consumables in each lab



Active Catheter Imaging – combining passive Tracking and active MR tracking

Passive Tracking

Passive tracking is a technique used for visualising and tracking a catheter within a patient where the intrinsic material characteristics of the catheter allow it to be seen in the MR image.

Refer Imricor's prospectus section 2.7.1 for further information.

Active Catheter Imaging

Combines Passive Tracking and Active MR Tracking to provide improved catheter visualisation without the need for 3rd party Active Tracking/Mapping software



Active MR Tracking and Mapping



Active MR tracking is a technique for tracking a catheter within a patient undergoing MRI using sensors that are embedded in the device.

3D mapping and tracking tools can provide a three dimensional representation of a patient's heart, and can use a tracked catheter to take electrical measurements inside the heart which can be represented as a colour map on top of the heart shell.

Refer Imricor's prospectus section 2.5 and 2.7.3 for further information.

Lab start-up comparison with and without Active Catheter Imaging on Siemens MRI



Active catheter imaging enables sites with an available Siemens MRI lab and the required equipment and training to commence procedures immediately following installation of the Advantage-MR System

Timeline is indicative only and not drawn to scale

Supporting market awareness and education

Experience the Future of Cardiac Ablation

Dr. Thomas Gaspar and Dr. Stefan Ulbrich from the Dresden Heart Centre discuss their successes performing cardiac ablation utilising real-time MR imaging

https://www.youtube.com/watch?v=qjXiMWuuvDI

Dose reduction in arrhythmia therapy

Moderated by Philipp Sommer, MD

Radiation-free iCMR ablation

Ivo Van Der Bilt, MD

https://cardiovascular-webinars.siemens-healthineers-events.com/signup/landing

Transforming Cardiac Ablation Procedures

Imricor corporate procedural video

https://vimeo.com/438663377

Contact information

Investors:
Steve Wedan
Executive Chair, President & CEO
Email: steve.wedan@imricor.com

Investors & Australian Media:
Carrie Barrack
Cato & Clive
Email: carrie@catoandclive.com

Rest of World Media:
Nick Twohy
Director of Marketing, Imricor
Email: nick.twohy@Imricor.com
Phone: +1 952 818 8407